Zhejiang Doer Biologics
CompanyChina
Zhejiang Doer Biologics develops one asset, approved (icosapent ethyl in Angina, Unstable). Mostly small molecule acting on lipid and ceramide metabolism and inflammation; based in China.
- 1
- Asset
- Furthest stage
- Approved
- 2
- Trials
- 7
- Signals
Pipeline
1Ethyl ester of eicosapentaenoic acid that lowers triglyceride levels
Approved, Small molecule, Lipid and ceramide metabolism, Inflammation, Angina, Unstable, cardiovascular disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Signals13
- Similar companies6